Show simple item record

dc.contributor.authorKennedy, Norman J.
dc.contributor.authorSluss, Hayla Karen
dc.contributor.authorJones, Stephen N.
dc.contributor.authorBar-Sagi, Dafna
dc.contributor.authorFlavell, Richard A.
dc.contributor.authorDavis, Roger J.
dc.date2022-08-11T08:10:03.000
dc.date.accessioned2022-08-23T16:53:11Z
dc.date.available2022-08-23T16:53:11Z
dc.date.issued2003-03-12
dc.date.submitted2008-07-15
dc.identifier.citation<p>Genes Dev. 2003 Mar 1;17(5):629-37. <a href="http://dx.doi.org/10.1101/gad.1062903">Link to article on publisher's site</a></p>
dc.identifier.issn0890-9369 (Print)
dc.identifier.doi10.1101/gad.1062903
dc.identifier.pmid12629045
dc.identifier.urihttp://hdl.handle.net/20.500.14038/42216
dc.description.abstractThe c-Jun NH(2)-terminal kinase (JNK) phosphorylates and activates members of the activator protein-1 (AP-1) group of transcription factors and is implicated in oncogenic transformation. To examine the role of JNK, we investigated the effect of JNK deficiency on Ras-stimulated transformation. We demonstrate that although JNK does play a role in transformation in vitro, JNK is not required for tumor development in vivo. Importantly, the loss of JNK expression resulted in substantial increases in the number and growth of tumor nodules in vivo. Complementation assays demonstrated that this phenotype was caused by JNK deficiency. These data demonstrate that, in contrast to expectations, the normal function of JNK may be to suppress tumor development in vivo. This conclusion is consistent with the presence in human tumors of loss-of-function mutations in the JNK pathway.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=12629045&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC196007/
dc.subjectAnimals
dc.subjectCell Line
dc.subjectCell Transformation, Neoplastic
dc.subjectFibroblasts
dc.subjectJNK Mitogen-Activated Protein Kinases
dc.subjectMale
dc.subjectMice
dc.subjectMice, Nude
dc.subjectMitogen-Activated Protein Kinases
dc.subjectNeoplasms, Experimental
dc.subjectSignal Transduction
dc.subjectras Proteins
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleSuppression of Ras-stimulated transformation by the JNK signal transduction pathway
dc.typeJournal Article
dc.source.journaltitleGenes and development
dc.source.volume17
dc.source.issue5
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/583
dc.identifier.contextkey549012
html.description.abstract<p>The c-Jun NH(2)-terminal kinase (JNK) phosphorylates and activates members of the activator protein-1 (AP-1) group of transcription factors and is implicated in oncogenic transformation. To examine the role of JNK, we investigated the effect of JNK deficiency on Ras-stimulated transformation. We demonstrate that although JNK does play a role in transformation in vitro, JNK is not required for tumor development in vivo. Importantly, the loss of JNK expression resulted in substantial increases in the number and growth of tumor nodules in vivo. Complementation assays demonstrated that this phenotype was caused by JNK deficiency. These data demonstrate that, in contrast to expectations, the normal function of JNK may be to suppress tumor development in vivo. This conclusion is consistent with the presence in human tumors of loss-of-function mutations in the JNK pathway.</p>
dc.identifier.submissionpathoapubs/583
dc.contributor.departmentDepartment of Cell Biology
dc.contributor.departmentDepartment of Cancer Biology
dc.contributor.departmentProgram in Molecular Medicine
dc.contributor.departmentHoward Hughes Medical Institute
dc.source.pages629-37


This item appears in the following Collection(s)

Show simple item record